New drug cocktail aims to tame kidney cancer

NCT ID NCT07401875

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether adding an experimental drug called HC-7366 to standard immunotherapy drugs (nivolumab and ipilimumab) can help control advanced clear cell kidney cancer. About 35 adults with stage IV disease will receive the combination. The main goal is to check safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HC-7366 combined with nivolumab and ipilimumab
What this could lead to: If successful, this could point toward a new combination treatment that helps control advanced kidney cancer when standard therapies stop working.
What could go wrong: This is a very early phase 1 trial with only 35 people, focused mainly on safety. The combination may not work better than existing options, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer nonpapillary renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HC-7366 KIDNEY CANCER PHASE 1B SHARK

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.